“This is a strategically important hire for Aegirbio” said Martin Linde, CEO of Aegirbio, in a statement. “Brandon’s prior experience in leading a diagnostic start-up to profitability within three short years is extremely valuable to us. As pandemic lockdowns are lifted in the United States he will be able to quickly start delivering on and accelerating our market position. We are on the verge of breakthroughs in both terms of Covid-19 testing and our core business of precisely dosing drugs.”
“Therapeutic drug monitoring is the next frontier in precision medicine” said Brandon Steele. “As drugs are increasingly directed towards only those patients who can benefit from them, further advances will rely on diagnostic tests that can reveal how well these targeted drugs are actually being metabolized. Aegirbio’s ability to precisely determine each patient’s drug levels will be crucial in minimizing drug toxicity, optimizing patient care, and lowering the cost of modern drug therapy.”
Steele most recently served as VP of Global Commercial Operations for Invivoscribe where he was responsible for launching many new NGS oncology tests to physicians, hospitals, and CLIA laboratories. Prior to his accomplishments there he held various senior management, sales, and marketing roles within IncellDx, Applied Imaging, Nanogen, Gen-Probe, and Bayer Diagnostics. Steele began his diagnostics career at Baxter International after advancing through a series of general management roles as a military officer. He received his B.S. from the United States Military Academy at West Point, NY.
ES 
EN